Inhibition of the Insulin-Like Growth Factor I Receptor by Epigallocatechin Gallate Blocks Proliferation and Induces the Death of Ewing Tumor Cells Free

It is widely reported that catechin derivatives contained in green tea have antineoplastic activity (1). One of these compounds, (−)-epigallocatechin gallate (EGCG), is a major component of green tea and has long been known to inhibit carcinogenesis of diverse tumor types (2–5). Recent studies have shown potential chemotherapeutic efficacy of EGCG against cancers of the skin, lung, breast, colon, liver, stomach, and prostate (6–8). As with many other natural dietary substances that have been studied in recent years as potential anticancer agents, EGCG is attractive as a potential therapeutic due to its lack of significant toxicity in normal cells (9).

EGCG has been reported to inhibit a variety of cancer-related pathways including cell proliferation and tumor growth (2, 8), invasion and metastasis (3, 4), and angiogenesis and to induce apoptosis and cell cycle arrest of transformed cells (8, 10, 11). Although it remains unclear how EGCG mediates these biological responses, one proposed mechanism is through the inactivation of receptor tyrosine kinases (RTK). Recently, EGCG was shown to inhibit members of the epidermal growth factor receptor family including epidermal growth factor receptor and ErbB2 (12–14). EGCG has also been reported to inhibit the activation of vascular endothelial growth factor receptor (15), platelet-derived growth factor receptor (16), and insulin-like growth factor I receptor (IGFIR; ref. 17). Other potential targets for inhibition by EGCG include signaling by NF-κB in colon cancer cells (5), cyclooxygenase-2 expression and activity (18, 19), and matrix metalloproteinases such as matrix metalloproteinase-2 and matrix metalloproteinase-9 that are involved in tumor cell invasion and metastasis (20). This broad spectrum of mechanistic possibilities for the antineoplastic actions of EGCG supports the need for further studies to identify its relevant molecular targets. For example, this agent may have different targets depending on the cellular context and it will be essential to identify specific targets in a given tumor type to optimize potential clinical benefits of EGCG for that disease.

Ewing family tumors (EFT) are the second most frequent bone tumors in children and young adults, and can also occur in the soft tissues (21, 22). EFTs are characterized by specific gene fusions involving the EWS gene on chromosome 22 and erythroblastosis-26 (ETS)-related genes such as FLI1 on chromosome 11 (23) or ERG on chromosome 21 (24). Many attempts have been made to elucidate the direct downstream targets that mediate transformation through EWS-FLI1 or EWS-ERG oncoprotein expression (25) Recently, new insights into the mechanism of EWS-ETS oncoproteins have been gleaned through more system-wide approaches (26). However, therapeutic targeting of EFT-associated chimeric transcription factors or their downstream pathways still remains extremely challenging.

In addition to EWS-ETS oncoproteins, EFTs are also reported to express several activated RTKs that likely contribute to the pathogenesis of EFT, including platelet-derived growth factor receptor, ERBB4, and IGFIR (27–29). Unlike chimeric transcription factors, RTKs are of interest therapeutically because of their potential druggability (30, 31). Recently, great interest has emerged in potentially targeting IGFIR in EFTs due to promise shown in early phase human clinical trials (29, 32, 33). Moreover, EWS-FLI1 requires the presence of IGFIR to transform mouse fibroblasts and IGFIR inhibition results in reduced tumorigenicity and metastasis of EFT cell lines (29). EWS-ETS fusion proteins induce IGFI promoter activity and an IGFI/IGFIR autocrine loop has been shown in EFTs (34, 35). EWS-FLI1 is also reported to repress IGFBP3, a negative regulator of IGFIR signaling (36). Finally, there is recent evidence that in childhood sarcomas, sensitivity to IGFIR blocking antibodies is linked to receptor levels (37). IGFIR is a transmembrane heterotetramer consisting of two α and β subunits. The two major ligands for IGFIR are IGFs 1 and 2, and the biological activities of these ligands are themselves controlled by a family of IGF binding proteins (38). Ligand binding results in IGFIR autophosphorylation and the activation of several downstream signaling pathways including phosphoinositide 3-kinase (PI3K)-Akt, Ras-Erk, and Jak-Stat cascades. Here, we show that EGCG causes growth inhibition and the apoptosis of EFT cell lines and that this is associated with marked inhibition of IGFIR autophosphorylation and downstream signaling pathways.

Two EFT cell lines, TC32 and TC71, have previously been described (39, 40). Cells were grown in 5% CO₂ in RPMI supplemented with 10% fetal bovine serum, 2 mmol/L glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (Life Technologies/Bethesda Research Laboratories). Human brain microvascular endothelial cells (HBMECs) were grown in the same condition. For anchorage-independent (spheroid) cultures, monolayer cells were trypsinized, resuspended as single cells, and replated on tissue culture dishes coated with 1.5% agar as described (28, 41, 42). EGCG was purchased from Sigma. The Annexin V–FITC apoptosis detection kit was purchased from Beckman Coulter. IGFI and cyclolignan picropodophyllin (PPP) were purchased from R&D Systems and Calbiochem, respectively.

Harvested cells were rinsed thrice in PBS containing 100 μmol/L Na₃VO₄ and then lysed in NP40 Lysis buffer (50 mmol/L HEPES, 100 mmol/L NaF, 10 mmol/L Na₄P₂O₇, 2 mmol/L Na₃VO₄, 2 mmol/L EDTA, 2 mmol/L NaMoO₄, and 0.5% NP40) containing a commercial protease inhibitor cocktail (Roche) for 30 minutes at 4°C with shaking. Following solubilization, protein concentrations were quantitated using the DC Bio-Rad Protein assay kit (Bio-Rad Laboratories). Following electrophoretic transfer to Immobilon-P membranes (Millipore), Western blot analysis was done using the indicated antibodies, including rabbit anti–poly (ADP-ribose) polymerase (PARP) antibody, anti–phospho-AKT Ser-473, anti–total AKT, anti–phospho-mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 Ser-217/221, anti-Jak2, anti-Bcl2, anti-Bax and anti–phospho-IGFIR (Tyr-1132) antibodies (Cell Signaling), anti–β-actin rabbit polyclonal antibody, anti-IGFIR rabbit polyclonal antibodies, (Santa Cruz), and 4G10 anti-phosphotyrosine mouse monoclonal antibodies (Upstate). Secondary anti-mouse and anti-rabbit horseradish peroxidase (HRP)–conjugated antibodies were from BD Transduction Laboratories. For immunoprecipitation, whole-cell lysates were prepared as above and 500 μg cell lysates were precleared with Protein G agarose (Pierce) at 4°C for 1 hour. Precleared lysates were then incubated with appropriate antibodies overnight at 4°C. Protein G agarose was added to the mixture and incubated at 4°C for 1 hour. Beads were collected by centrifugation and washed thrice with the above lysis buffer. Proteins were eluted by boiling in SDS sample buffer and subjected to immunoblotting using appropriate antibodies.

All cytotoxicity assays were done in 96-well tissue culture plates using a semiautomated digital image microscopy scanning system (DIMSCAN), which has a dynamic range of four logs of cell kill as described (28, 43). Briefly, TC32, TC71 cells, and HBMEC were plated at 5,000 cells with 100 μL of complete medium per well. Cells were cultured for 1 day before the addition of concentration ranges of EGCG (0–100 μmol/L; Sigma-Aldrich) in complete medium in replicates of 12 wells per condition. Plates were assayed 2 and 3 days after the initiation of EGCG treatment. To measure cytotoxicity, fluorescein diacetate was added to the plates to 10 μg/mL and incubated for 20 minutes. Then, 30 μL of eosin-Y (0.5% in normal saline) were added to quench background fluorescence (28, 43). Total fluorescence per well was then measured using a proprietary DIMSCAN system and results were expressed as the fractional survival of treated cells versus control cells. For apoptosis studies, spheroid and monolayer cells were treated with different concentrations of EGCG (0–100 μmol/L). Following treatment of EGCG, harvested cells were lysed with the NP40 lysis buffer and caspase-3 activity assay or Western blotting were done using appropriate antibodies.

To investigate the effect of EGCG on cell proliferation, we used a bromodeoxyuridine (BrdUrd) cell staining kit (Calbiochem) according to the manufacturer's protocol. Briefly 5,000 cells were inoculated into 96-well plates and grew for 24 hours. Then, the cells were incubated with BrdUrd for 5 hours and fixed with fixative/denaturing solution. BrdUrd-incorporated cells were incubated with anti-BrdUrd antibody and detected with HRP–conjugated anti-mouse secondary antibody using tetra-methylbenzidine solution. Measurement of absorbance in each well was done using the GENiosPro instrument (Tecan) at 450 nm.

Soft agar assays were performed by seeding cells in triplicate at a concentration of 2,000 cells per well of six-well plates as previously described (28, 44). Plates were incubated for 14 days before being photographed and counted. Results shown are representative of three independent assays.

Caspase-3 activity was assayed by Z-DEVD-AFC cleavage according to the manufacturer's protocols (Calbiochem). Briefly, cells grown under the indicated conditions were lysed at 4°C and lysates were incubated with reaction buffer containing 50 μmol/L Z-DEVD-AFC. After incubation at 37°C, fluorescence was measured with a GENiosPro instrument (Tecan). Caspase-3 activity was adjusted for protein concentration and relative activity was expressed as the fluorescence ratio between the normalized caspase-3 activity of nontreated cells (relative unit of 1.0) versus treated cells.

For the analysis of cell cycle, cells treated with or without EGCG were harvested, fixed with 70% ethanol, washed twice with PBS, and treated with RNase A. The fixed cells were stained with propidium iodide (PI). The fractions of different cell cycle cells were analyzed using BD LSR II flow cytometer (BD Biosciences) with the DiVA (version 4.1.2) software. To analyze apoptosis, cells were washed with PBS and incubated with anti–Annexin V-FITC (BD Biosciences) for 1 hour at room temperature. After washing cells with PBS, PI was added and the cells were incubated for 30 minutes. Then, the labeled cells were analyzed by flow cytometry.

TC32 and TC71 cells were grown for 48 hours in 10% serum–containing medium, followed by further 24 hours with or without 50 μmol/L EGCG. Cells were then washed thrice with PBS containing 100 μmol/L Na₃VO₄ and lysed in lysis buffer as previously described (28). Following lysis, 300 μg of total protein was incubated with Human Phospho-RTK Arrays (R&D Systems) according to the manufacturer's protocols. Briefly, arrays were incubated with whole-cell lysates overnight at 4°C with shaking and washed with supplied washing buffer. Arrays were then incubated with anti–phosphotyrosine-HRP antibodies conjugated with HRP for 2 hours at room temperature on a rocking platform shaker, before incubation with a chemiluminescent reagent and film exposure.

As a first step in evaluating the potential effects of EGCG on EFTs, we determined the cytotoxicity profiles of this agent against cultured TC32 and TC71 cells, two previously characterized EFT cell lines that both express the type I EWS-FLI1 gene fusion (39, 40). Dose-dependent fractional survival of these and control normal HBMECs (45) in the presence and absence of EGCG was compared using the DIMSCAN drug sensitivity screening platform as previously described (28, 43). HBMECs were chosen as a controls as these are human and mesenchymal derived and have very low IGFIR levels (Supplementary Fig. S1A). EGCG treatment showed very weak cytotoxic effects on HBMEC cells and only at high (100 μmol/L) levels and this was evident even after 5 days. On the other hand, TC32 cells were sensitive at concentrations of 25 μmol/L levels or less (Fig. 1A). TC71 cells were less sensitive than TC32 cells but still showed significant cytotoxicity at a 50 μmol/L concentration. The reason for this discrepancy between TC32 and TC71 cells remains unknown. These results indicate that EFT cells are sensitive to EGCG treatment at concentrations that are ineffective at inducing cytotoxicity in normal HBMEC cells.

We next wished to determine the effects of EGCG on EFT cell growth. TC32 and TC71 cells were treated with 0 to 100 μmol/L EGCG over a time course of 0 to 96 hours and viable cell numbers were monitored. As shown in Fig. 1B, EGCG treatment produced moderate concentration-dependent inhibition of growth in both TC32 and TC71 cell lines but not in HBMECs. To further investigate effects on cell proliferation, all three cell lines were cultured in the presence of 50 μmol/L EGCG for 24 hours and cell proliferation was determined by BrdUrd staining. As shown in Fig. 1C, EGCG dramatically inhibited BrdUrd uptake in EFT cell lines but not in HBMECs. These results indicate that EGCG has tumor-specific inhibitory effects on the proliferation of EFT cells.

We next determined whether the observed effects of EGCG on EFT cell growth are related to the induction of apoptosis. We first assessed morphologic changes of EFT cells treated with EGCG. As shown in Fig. 2A, EGCG treatment of TC32 and TC71 cells induced morphologic changes suggestive of apoptosis, including cell rounding and detachment from the plates. In contrast, these changes were not detected in EGCG-treated HBMECs. The proapoptotic effects of EGCG were further assessed by caspase-3 activation assays in cultures treated with varying concentrations of EGCG. As shown in Fig. 2B, caspase-3 activity showed a dose-dependent increase in TC32 and TC71 cells, which in contrast was not observed in HBMECs. Moreover, we observed marked cleavage of PARP, a well-known caspase-3 substrate, in EFT cells but not in HBMECs after 24 hours of EGCG treatment (Fig. 2C). Flow cytometry was then done to examine effects of EGCG on the cell cycle of EFT cells. As shown in Fig. 3A, EGCG treatment caused only minimal alterations in cell cycle profiles of TC32 or TC71 cells, with slight accumulation of treated cells in the G₀-G₁ phase. In contrast, when TC32 cells (and TC71 cells; data not shown) were analyzed by Annexin V and PI staining, there was a dramatic increase in apoptotic cells following EGCG treatment (Fig. 3B), which was not observed in HBMECs (Fig. 3C). The percentage of apoptotic TC32 cells increased in a dose-dependent fashion, with ∼90% apoptotic cells after treatment with 25 μmol/L EGCG. These results indicate that the predominant effect of EGCG on EFT cells may be through the induction of apoptosis, with a possible minor effect in inducing cell cycle arrest. Therefore, EGCG specifically induces EFT cell apoptosis.

We next examined the effects of EGCG on the anchorage-independent growth of EFT cells using soft agar colony assays. As shown in Fig. 4A and B, TC32 and TC71 cells treated with two different concentrations of EGCG (50 and 100 μmol/L) showed a dose-dependent reduction in the size and number of colonies in soft agar. Similar to the cytotoxicity results of Fig. 1, TC32 were more sensitive than TC71 cells to EGCG treatment in these assays. We also analyzed EGCG effects on anchorageindependent growth by culturing cells on agar-coated plates as described to induce multicellular spheroid formation (28). As shown in Supplementary Fig. S1B, spheroid formation was dramatically reduced in the presence of 50 μmol/L EGCG. This correlated with a marked increase in caspase-3 activity in EGCG-treated cells (Supplementary Fig. S1C). Taken together, these results indicate that the target of EGCG in EFT cells might not only be involved in cell survival of EFT monolayer cells but also in anchorage-independent cell growth and survival.

To test which signaling pathways might be targeted as part of the mechanism of action of EGCG, we first assessed the effects of EGCG on the PI3K-Akt and Ras-Erk pathways, two cascades that are well known to mediate tumor cell growth and survival. To do this, we monitored the activation states of molecules involved in these pathways by Western blot analysis using phospho-specific antibodies. As shown in Fig. 4C, treatment of TC32 and TC71 cells with EGCG resulted in a dosedependent reduction of phospho-Akt (Ser-473) and, to a lesser extent, phospho-Erk1/2, as read-outs of PI3K-Akt and Ras-Erk signaling, respectively. In contrast, Akt and Erk1/2 phosphorylation was unaffected by treatment of HBMECs with EGCG, indicating that EGCG selectively inhibits PI3K-Akt and Ras-Erk signaling in EFT cells. Because EGCG treatment of TC32 and TC71 cells predominantly induces apoptosis (see above), we next compared potential downstream effector molecules of PI3K-Akt and/or Ras-Erk pathways that regulate apoptosis. Bcl-2 family proteins consist of both proapoptotic and prosurvival molecules, and homodimerization and heterodimerization of these proteins play key roles in the transduction and integration of apoptosis (46). We therefore examined the expression of a panel of Bcl-2 family proteins known to be regulated through PI3K-Akt and/or Ras-Erk pathways. As shown in Fig. 4C, treatment of EFT cells with EGCG resulted in a dosedependent reduction of prosurvival members such as Bcl-2, Bcl-XL, and Mcl-1, whereas expression of the proapoptotic Bax protein was induced by EGCG treatment. These results provide preliminary evidence that EGCG-mediated induction of apoptosis in EFT cells may involve alterations in Bcl-2 family proteins and that this may occur through inhibition of PI3K-Akt and/or Ras-Erk signaling.

Because EGCG inhibits both PI3K-Akt and Ras-Erk signaling in EFT cells, we wondered whether this agent might be targeting specific RTKs in EFT cells, particularly because this agent has been reported to block RTKs (1). To test this, we used the R&D Systems Human Phospho-RTK Antibody Proteome Profiler Array of 42 different tyrosine kinases (47), which we previously used to screen for RTK activation in EFT cell lines (28). Lysates from TC32 and TC71 cell lines grown in 10% serum–containing media with or without EGCG showed reduced activation of several RTKs in 50 μmol/L EGCG-treated cells. Of these, the most prominent reduction in RTK tyrosine phosphorylation in both cell lines was observed for IGFIR (see Fig. 5A). To validate this, TC32 and TC71 lysates were subjected to IGFIR immunoprecipitation followed by immunoblotting with anti-phosphotyrosine antibodies. This showed dramatic decreases in IGFIR tyrosine phosphorylation in EGCG-treated compared with nontreated cells, whereas total IGFIR levels were unchanged (Fig. 5B). Identical results were obtained when cells were first serum starved overnight and then stimulated with 50 ng/mL IGFI for 3 hours in the presence or absence of EGCG. As shown in Fig. 5C, exogenous IGFI stimulated IGFIR phosphorylation, but this was almost completely blocked by treatment with EGCG. As a positive control, we also treated cells with PPP, a known inhibitor of IGFIR in diverse tumor types (48). As shown in Supplementary Fig. S2A and B, treatment of TC32 and TC71 cells with increasing levels of PPP showed dose-dependent increases in caspase-3 activation and PARP cleavage as in vitro markers of apoptosis. Similar to EGCG, PPP treatment correlated with the loss of IGFIR tyrosine phosphorylation (Supplementary Fig. S2C). In contrast, PPP had no significant effects on cell growth or apoptosis of HBMECs (data not shown). Although our findings do not rule out the effects of EGCG and PPP on other pathways, they are consistent with these agents directly or indirectly targeting IGFIR.

To independently validate that effects of EGCG on transformed mesenchymal cells are indeed related to blocking the IGFIR pathway, we used a different model system to study this process. We previously identified the ETV6-NTRK3 (EN) chimeric tyrosine kinase as a transforming oncoprotein in congenital fibrosarcoma (49) and secretory breast cancer (50). EN requires a functional IGFIR axis for transformation (42, 51) and is incapable of transforming mouse embryo fibroblasts lacking IGFIR (so-called R− cells). However, EN transformation is restored when R− cells are engineered to reexpress IGFIR (so-called R+ cells; ref. 42). We previously showed that when EN is constitutively membrane targeted using a myristoylation tag (designated ENmyr), then cells no longer require IGFIR for transformation and the ENmyr mutant is capable of transforming R− cells (42). We therefore compared the EGCG sensitivity of R+EN cells (IGFIR+/EN+) versus R-ENmyr cells (IGFIR-/ENmyr+; Supplementary Fig. S3A), both of which are transformed (42). As shown in Supplementary Fig. S3B, EGCG induces caspase-3 activation only in R+EN (and R+ control cells) but not in IGFIR-deficient R-ENmyr cells. Moreover, EGCG only blocks the soft agar colony formation of R+EN cells and not R-ENmyr cells, which lack IGFIR (Supplementary Fig. S3C and D). Neither R+, as shown, nor R-EN cells (data not shown) formed colonies in soft agar, as previously reported (42). Collectively, these data provide compelling evidence that the observed EGCG cytotoxic effect on transformed mesenchymal cells is related to IGFIR expression.

As additional evidence that EGCG targets IGFIR signaling, we next examined whether, in addition to PI3K-Akt and Ras-Erk cascades (Fig. 4C), EGCG inhibits other known downstream effector pathways of IGFIR. Recent studies suggest cross-talk between IGFIR signaling and the Jak-Stat pathway and that IGFIR can activate the Jak2-Stat3 cascade (52–54). We therefore examined whether EGCG could modulate Jak-Stat signaling in EFT cells. As shown in Supplementary Fig. S2D, EGCG strongly inhibited tyrosine phosphorylation of Jak2, Stat1, Stat3, and Stat5, whereas Stat2 and Stat6 were unaffected. Jak2-Stat signaling was not activated in HBMEC lines (data not shown). Although this does not prove that IGFIR inhibition by EGCG directly blocks Jak2-Stat activation, our data provide preliminary evidence for an IGFIR-Jak2-Stat1/3/5 axis in EFT cells that is inhibited by EGCG.

We next wished to determine whether EGCG inhibits IGFIR signaling in childhood sarcomas other than EFTs. We therefore treated the rhabdomyosarcoma cell lines, HR and JR, and the osteosarcoma cell lines, OST and SaOS2, with 0 to 100 μmol/L EGCG and assessed cellular responses as described above. EGCG inhibited cell proliferation (Fig. 6A) and induced apoptosis of each of these cell lines in a dose-dependent fashion (Fig. 6B and C), although there was variability in the responses among the cell lines. Next, we examined whether these effects of EGCG correlate with inhibition of IGFIR as observed for EFT cell lines. As shown in Fig. 6D, EGCG inhibited the activation of IGFIR, although again with some variability among cell lines. These results provide preliminary evidence that EGCG can inhibit IGFIR in a potentially broader spectrum of childhood sarcoma cells.

The polyphenol catechin EGCG is a major component of green tea that has been a worldwide dietary component for over 5,000 years (55). EGCG has variably been reported to possess antioxidant, antimutagenic, antidiabetic, anti-inflammatory, antibacterial, and anticancer properties. Epidemiologic research has shown that the frequency of green tea consumption correlates with reduced rates of cancer development or recurrence in diverse tumor types, including breast cancer (56). Although the exact targets of EGCG remain unknown, it is currently thought to modify the activities of various RTKs and/or signal transduction pathways acting downstream of these proteins (1). Clearly, a better understanding of the fundamental mechanism of action of EGCG is needed to more effectively use this compound as a cancer therapeutic or preventive agent, particularly in combination with other therapeutics (9, 55). To our knowledge, EGCG has not yet been tested in childhood sarcomas such as EFTs. Here, we show that in the well-established EFT cell lines, TC32 and TC71, EGCG treatment led to marked growth inhibition, induction of apoptosis, and a block in activation of the IGFIR pathway at micromolar concentrations. EGCG treatment led to the inhibition of Ras-Erk, PI3K-Akt, and Jak2-Stat signaling in EFT cells; to the loss of expression of the prosurvival factors Bcl-2, Bcl-XL, and Mcl-1; and to the increased expression of the proapoptotic Bax protein.

In normal cells, expression and activation of RTKs and their ligands are precisely regulated, but in many cancers, these controls are lost or altered. Therefore, RTKs or other activated protein tyrosine kinases are considered as attractive therapeutic targets in tumor cells (31). However, many currently available RTK inhibitors, including small-molecule kinase inhibitors and blocking antibodies, have significant toxicities (57). Therefore, a low toxicity agent such as EGCG that augments RTK inhibition would be highly desirable. In a screen for tyrosine kinases that might be targeted by EGCG in EFTs, we found that IGFIR is highly activated in EFTs under 10% serum growth conditions and that EGCG dramatically blocks IGFIR tyrosine phosphorylation. Moreover, Ras-Erk, PI3K-Akt, and Jak2-Stat1/3/5 pathways, which are known downstream cascades of IGFIR, were also blocked by EGCG. Similar results were observed with the PPP, a well-established IGFIR inhibitor. In contrast, effects were not observed in nontransformed HBMECs, whose IGFIR expression levels are much lower than in EFT cell lines (Supplementary Fig. S1A). These studies support the notion that EGCG either directly or indirectly targets IGFIR in these cells.

IGFIR has previously been suggested as a potential target for EGCG. Recently, it was shown that the IGFIR binds EGCG in R− mouse embryo fibroblast cells, derived from mice with a targeted disruption of the Igf1R locus, once these cells were engineered to reexpress IGFIR (so-called R+ cells; ref. 58). EGCG had little or no effect on the growth of parental R− cells, but expression of IGFIR restored the sensitivity of the cells to EGCG-mediated apoptosis (58). In that study, it was also reported that EGCG could directly inhibit the kinase activity of IGFIR through competitive binding to the ATP binding pocket of the IGFIR protein. We therefore performed cytotoxicity assays of EGCG using R− and R+ cells stably expressing the EN chimeric tyrosine kinase, generated by the t(12;15) translocation of congenital fibrosarcoma and secretory breast cancer, or an EN mutant, ENmyr, which is constitutively targeted to the plasma membrane (42). Although EN is incapable of transforming R− cells, similar to most known dominantly acting oncoproteins (59), membrane-targeted ENmyr no longer requires IGFIR for transformation and can transform both R− and R+ cells (42). EGCG only blocks the soft agar colony formation of R+EN cells whereas R-ENmyr cells were unaffected by EGCG treatment (as were R+ENmyr cells; data not shown). These studies provide strong evidence that EGCG cytotoxicity of EFT and potentially other sarcoma cells is functioning through the inhibition of IGFIR or a component of the IGFIR pathway. However, our data also do not address whether IGFIR is a direct in vivo target of EGCG in EFT cells or whether EGCG is targeting EFT cells because they are highly IGFIR dependent. Recent evidence suggests that IGFIR may be the major activator of the PI3K-Akt pathway in childhood sarcoma cells and therefore these tumors would be expected to be susceptible to an agent that blocks the IGFIR pathway. It is also conceivable that EGCG targets other RTKs, common downstream components of multiple RTKs, or activates a phosphatase negatively regulating IGFIR (and/or other RTKs). Indeed, we found that the Janus kinase Jak2 as well as its downstream effectors Stat1, Stat3, and Stat5 (but not Stat2 or Stat6) are activated in EFTs and that this process is blocked by EGCG. Jak-Stat signaling is involved in diverse cellular processes including proliferation, survival, and differentiation (60). Tyrosine phosphorylation of Stat3 has been described in EFTs (61), but to our knowledge Jak-Stat signaling has not been otherwise evaluated in these tumors. Although EGCG may target Jak2 directly, several studies suggest that tyrosine phosphorylation of Jak2 and Stat3 is induced by IGFI-mediated activation of IGFIR (52–54). Therefore, the effects of EGCG on Jak2-Stat signaling may then, through its ability to block IGFIR, inhibit the downstream Jak2-Stat3 cascade. Further studies are required to elucidate whether the inhibition of Jak-Stat signaling by EGCG is dependent on IGFIR inhibition.

We also tested the effects of EGCG on other childhood sarcoma cell lines, including rhabdomyosarcoma (JR and HR) and osteosarcoma (OST and SaOS2) cell lines. Similar to EFT cells, EGCG treatment resulted in a block in proliferation, increased apoptosis, and loss of IGFIR tyrosine phosphorylation in these cell types. Although preliminary, our data suggest that EGCG should be evaluated as a potential therapeutic in a broader spectrum of childhood sarcomas. In the present study, we observed in vitro efficacy at concentrations of 25 to 100 μmol/L. Although this range is several orders of magnitude higher than is desirable for most molecular therapeutics, the low toxicity profile of EGCG may allow for clinical use. In particular, EGCG may be of benefit in combination with other RTK small-molecule inhibitors or blocking antibodies such as those targeting IGFIR. Inclusion of EGCG in the treatment of EFT with other IGFIR inhibitors might then allow for decreased dosing of the latter in therapeutic regimens, leading to lower overall toxicity profiles.

No potential conflicts of interest were disclosed.

We thank Dr. Stuart Siegel for support and helpful discussions.

Grant Support: Ronald A. and Victoria Mann Simms Foundation, the Fannie Ripple Foundation, the David Paul Kane Foundation, and the Melanie Silverman Bone and Soft Tissue Fund (P.H.B. Sorensen), and U.S. Department of Defense grant W81XWH-07-1-0580 (P.H.B. Sorensen, C.P. Reynolds, and T.J. Triche).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.